ModifiedPremera BluecrossPolicy N/A

Radiofrequency volumetric tissue reduction and ablation for nasal obstruction (internal nasal valve collapse and nasal swell body reduction)

This policy governs coverage for radiofrequency volumetric tissue reduction (RFVTR) for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction in members of Premera Blue Cross; it summarizes evidence, coding, and coverage stance for these procedures.

Policy Summary

PayerPremera Bluecross

PolicyRadiofrequency volumetric tissue reduction and ablation for nasal obstruction (internal nasal valve collapse and nasal swell body reduction)

Policy CodePolicy N/A

Change TypeNew policy — investigational determinations addedHCPCS codes added

Effective DateApr 8, 2025

Next Review DateN/A

Key ActionObtain prior authorization or expect possible denial for procedures considered investigational (e.g., RFVTR or RF/cryoablation for nasal swell body or internal nasal valve).

SourceLink

POLICY UPDATE CHANGES

Radiofrequency volumetric tissue reduction for nasal obstruction due to internal nasal valve collapse is considered investigational.

Radiofrequency ablation or cryoablation for nasal swell body reduction for the treatment of nasal obstruction is considered investigational.

HCPCS codes 30117 and 30469 were added to the policy.

InvestigationalRFVTR coverage stance

InvestigationalRF/cryoablation NSB stance

1 RCT + reviewsKey evidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Apr 8, 2025Effective

Coverage Criteria and Policy Stance

Investigational — Not medically necessary

The following services are considered investigational (not established as medically necessary):

RFVTR for internal nasal valve collapse: Radiofrequency volumetric tissue reduction for nasal obstruction due to internal nasal valve collapse (e.g., VivAer Stylus) is considered investigational.

RF/cryoablation for nasal swell body reduction: Radiofrequency ablation or cryoablation for nasal swell body reduction for the treatment of nasal obstruction is considered investigational.

Investigational / Not Medically Necessary

Not medically necessary / investigational when any of the following apply:

Investigational procedures: Radiofrequency volumetric tissue reduction for nasal obstruction due to internal nasal valve collapse is considered investigational.

Added to Surgery section of new policy

Investigational procedures: Radiofrequency ablation or cryoablation for nasal swell body reduction for the treatment of nasal obstruction is considered investigational.

Added to policy statements

Radiofrequency volumetric tissue reduction (RFVTR) for nasal obstruction due to internal nasal valve collapse (e.g., VivAer Stylus) and radiofrequency ablation or cryoablation for nasal swell body reduction for the treatment of nasal obstruction are both designated investigational (not established as medically necessary) and are excluded from coverage.

This medical policy governs coverage determinations for the listed procedures but does not apply to Medicare Advantage members; member-specific benefits and limitations should be confirmed through the member benefit booklet or customer service.

Available evidence for RFVTR in internal nasal valve collapse includes systematic reviews and a randomized controlled trial with short-term controlled follow-up and uncontrolled longer-term follow-up; while some studies report improvement in nasal obstruction scores and a statistically significant 3‑month benefit in the RCT, limitations (small sample size, short duration, limited generalizability, and potential confounding) prevent definitive conclusions. For nasal swell body reduction, evidence consists of retrospective studies, a systematic review, single‑arm series and a small RCT showing symptomatic improvement but lacking robust, long‑term controlled data. Overall, the evidence is insufficient to demonstrate an improvement in net health outcome for these procedures.

Accordingly, radiofrequency volumetric tissue reduction for internal nasal valve collapse and radiofrequency ablation or cryoablation for nasal swell body reduction are considered investigational / not medically necessary and may be denied as not medically necessary when billed for these indications.

Coding and Regulatory References

Nasal swell body reduction CPTCPT

30117

Excision or destruction (e.g., laser), intranasal lesion; internal approach (use to report: nasal swell body reduction)

Internal nasal valve radiofrequency CPTCPT

30469

Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling (use to report: VivAer Nasal Airway Remodeling)

HCPCS codes addedHCPCS

30117	HCPCS code added (as listed in policy history)
30469	HCPCS code added (as listed in policy history)

FDA 510(k) referencesmixed

K200300	VivAer Stylus 510(k) Premarket Notification
K172529	Predicate device (Vivaer ARC Stylus) referenced in FDA summary

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization for Added Codes

Prior authorization may be required for recently added HCPCS/CPT codes before scheduling treatment.

Affected codes: CPT 30117 (nasal swell body reduction) and CPT 30469 (VivAer nasal airway remodeling).
Check member benefits and obtain prior authorization if applicable to the member’s plan before performing these procedures.

Denial Risk

Investigational Procedures — Potential Denial

RF volumetric tissue reduction (RFVTR) for internal nasal valve collapse, and radiofrequency or cryoablation for nasal swell body reduction, are considered investigational under this policy and may be denied.

Procedures described (e.g., VivAer Stylus RFVTR) are listed as investigational and are subject to denial.
Providers should be aware that claims for these services may be reviewed and denied as not medically necessary per this policy.

Clinical Background

Nasal obstruction may arise from several anatomic contributors. Internal nasal valve collapse (NVC) involves narrowing of the narrowest portion of the nasal airway formed by the upper and lower lateral cartilages, anterior inferior turbinate, and septum and is a major source of nasal airflow resistance. An enlarged nasal swell body (septal swell body) is an area of thickened mucosa and tissues on the anterior septum located superior to the inferior turbinate that can also impede airflow. Clinical assessment typically includes history and targeted physical maneuvers (e.g., Cottle or modified Cottle) to differentiate internal valve dysfunction from other causes and to define the specific anatomic target for intervention.

Key Definitions and Device Distinctions

Nasal swell body (septal swell body) definition

TermNasal swell body (septal swell body)

Anatomic descriptionEnlarged region of the anterior nasal septum located superior to the inferior turbinate and anterior to the middle turbinate; composed of septal cartilage, bone, and thick mucosa

Clinical relevanceMay interfere with airflow and humidification due to proximity to the internal nasal valve; can be associated with allergic rhinitis, chronic rhinosinusitis, and septal deviation

Location detailSituated on anterior septum, superior to inferior turbinate and anterior to middle turbinate

Internal nasal valve (NVC) definition

TermInternal nasal valve (NVC)

Policy Summary

PayerPremera Bluecross

PolicyRadiofrequency volumetric tissue reduction and ablation for nasal obstruction (internal nasal valve collapse and nasal swell body reduction)

Policy CodePolicy N/A

Change TypeNew policy — investigational determinations addedHCPCS codes added

Effective DateApr 8, 2025

Next Review DateN/A

Key ActionObtain prior authorization or expect possible denial for procedures considered investigational (e.g., RFVTR or RF/cryoablation for nasal swell body or internal nasal valve).

SourceLink

On This Page

Denial Risk

Investigational Procedures — Denial Risk

There is explicit denial risk for RFVTR and RF/cryoablation procedures described in this policy; submit full documentation if requesting review but anticipate non-coverage.

Anticipate claim denial for RF volumetric tissue reduction for internal nasal valve collapse and for radiofrequency or cryoablation of nasal swell body for nasal obstruction.
If appealing, reference supporting clinical evidence and rationale for medical necessity; appeals should include detailed clinical documentation.

Documentation Required

Required Clinical Documentation

Document the clinical history and findings thoroughly in the medical record to support any request for coverage or prior authorization.

History: symptoms, duration, prior conservative treatments and response, prior surgeries, and contributing comorbidities.
Physical exam: detailed nose, nasal cavity, and nasopharynx exam including external and internal nasal valve assessment; results of Cottle or modified Cottle maneuvers (subjective improvement documented).
Procedure-specific documentation: indication for procedure, target anatomic site (internal nasal valve vs nasal swell body), and rationale why conservative care is insufficient.

Documentation Required

Documentation Guidance (Device / Regulatory Status)

Include device- and procedure-specific regulatory and device-status information when relevant to requests or appeals.

When applicable, note FDA 510(k) status and clearance number (e.g., VivAer Stylus 510(k) K200300) and describe intended use per the clearance.
If using device-based interventions, include device name, model/stylus, manufacturer, and whether use aligns with cleared indications.
Provide citations to supporting peer-reviewed evidence if arguing for coverage despite investigational designation.

Documentation Required

Conservative Therapy Before Invasive Procedures

Conservative, non-surgical therapy should be attempted and documented prior to considering invasive procedures for nasal valve dysfunction.

Document trial and duration of conservative measures (e.g., external adhesive strips, nasal dilators/cones, internal support devices) and patient response.
If conservative measures failed or were unsuitable, document reasons for failure or contraindication to non-surgical therapy.

Note

Provider Action — Verify Requirements

Provider action placeholder: confirm payer-specific requirements and take appropriate actions (authorizations, documentation, appeals) as applicable.

Verify member benefits and any plan-specific prior authorization requirements.
When in doubt, contact Premera provider services for guidance on coverage and prior authorization processes.

Anatomic bordersBordered by upper and lower lateral cartilages, the anterior end of the inferior turbinate, and the nasal septum

Physiologic roleNarrowest portion of the nasal airway; accounts for at least half of nasal airway resistance and a major determinant of airflow

Clinical noteDynamic inward movement of lateral wall cartilage during inspiration can narrow the valve; damaged or weakened cartilage increases obstruction symptoms

VivAer Stylus — bipolar radiofrequency device cleared by FDA (K200300)

DeviceVivAer Stylus (Aerin Medical)

Regulatory statusFDA 510(k) cleared for use in ENT surgery (K200300)

Indication per 510(k)Cleared for coagulation of soft tissue in the nasal airway to treat nasal airway obstruction by shrinking submucosal tissue, including cartilage in the internal nasal valve area

MechanismDelivers bipolar radiofrequency energy to coagulate and shrink submucosal tissue

RhinAer device distinction — targets posterior nasal nerve for chronic rhinitis; different target/intended effect

Device distinctionRhinAer (Aerin Medical) is distinct from the VivAer Stylus

TargetRhinAer targets the posterior nasal nerve for disruption

Intended effectAimed at treating chronic rhinitis via nerve disruption rather than remodeling nasal valve tissue to improve airflow

Clinical implicationRhinAer differs in target and intended physiologic effect from devices that remodel internal nasal valve tissue